Original Articles

All Items

In general, this kind of publication should be divided into an Abstract, Introduction, Materials and Methods, Results, Discussion, Conclusions and References. [3500 words max, abstract 180 words max, 30 references max, 3/5 tables and/or figures]

  • Ankle brachial index for the diagnosis of asymptomatic lower extremity peripheral arterial disease

    Francesco Cicconi
    https://doi.org/10.4081/btvb.2024.128
    1152
    PDF: 296

  • Artificial intelligence, platelets and aspirin

    Giovanni de Gaetano
    https://doi.org/10.4081/btvb.2024.130
    340
    PDF: 156

  • Cancer complicated by thrombosis and thrombocytopenia: still a therapeutic dilemma

    Yishi Tan, Marc Carrier, Nicola Curry, Michael Desborough, Kathryn Musgrave, Marie Scully, Tzu-Fei Wang, Mari Thomas, Simon J. Stanworth
    https://doi.org/10.4081/btvb.2024.115
    501
    PDF: 161

  • Cancer-associated ischemic stroke: current knowledge and future directions

    Ronda Lun, Deborah M. Siegal
    https://doi.org/10.4081/btvb.2024.117
    1388
    PDF: 365

  • Endothelial cell dysfunction in cancer: a not-so-innocent bystander

    Betül Ünlü, Neha Joshi, Jamie M. O'Sullivan
    https://doi.org/10.4081/btvb.2024.116
    1047
    PDF: 174

  • Factor XI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis

    Marcello Di Nisio, Matteo Candeloro, Nicola Potere, Ettore Porreca, Jeffrey I. Weitz
    https://doi.org/10.4081/btvb.2024.118
    593
    PDF: 238

  • Location of metastasis and complications in patients with venous thromboembolism and cancer: a systematic review

    Maria Barca-Hernando, Victor Garcia-Garcia, Luis Jara-Palomares
    https://doi.org/10.4081/btvb.2024.114
    365
    PDF: 125

  • Machine learning in cancer-associated thrombosis: hype or hope in untangling the clot

    Rushad Patell, Jeffrey I. Zwicker, Rohan Singh, Simon Mantha
    https://doi.org/10.4081/btvb.2024.123
    1060
    PDF: 220

  • New drugs, old problems: immune checkpoint inhibitors and cancer-associated thrombosis

    Mehrie H. Patel, Alok A. Khorana
    https://doi.org/10.4081/btvb.2024.113
    371
    PDF: 187

  • Patient and public involvement in cancer-associated thrombosis research: necessary or glorified tokenism?

    Simon Noble
    https://doi.org/10.4081/btvb.2024.125
    1053
    PDF: 136

  • Risk of recurrent venous thromboembolism in cancer patients after discontinuation of anticoagulant therapy

    Gary E. Raskob
    https://doi.org/10.4081/btvb.2024.124
    434
    PDF: 180

  • Trends and updates on the epidemiology of cancer-associated thrombosis: a systematic review

    Ang Li, Emily Zhou
    https://doi.org/10.4081/btvb.2024.108
    528
    PDF: 204

  • Venous thromboembolism and mortality in patients with hematological malignancies

    Kristen M. Sanfilippo, Tzu-Fei Wang
    https://doi.org/10.4081/btvb.2024.119
    437
    PDF: 148

  • Venous thromboembolism treatment in patients with cancer: reflections on an evolving landscape

    Agnes Y.Y. Lee
    https://doi.org/10.4081/btvb.2024.111
    1299
    PDF: 233

  • Welcome to the 12th International Conference on Thrombosis and Hemostasis Issues in Cancer!

    Anna Falanga, Benjamin Brenner, Alok A. Khorana
    https://doi.org/10.4081/btvb.2024.138
    1295
    PDF: 193

  • Welcome to the 12th International Conference on Thrombosis and Hemostasis Issues in Cancer! Oral Communications and Posters

    Anna Falanga, Benjamin Brenner, Alok A. Khorana
    https://doi.org/10.4081/btvb.2024.139
    318
    PDF: 308